Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

Recruiting now

Conditions studied: AML - Acute Myeloid Leukemia

In brief

The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived? Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.

Key facts

Study ID
NCT06782971
Run by
Clinical Hub for Interventional Research (CHOIR)
People needed
25
Starts
2025-06-06
Expected to finish
2030-03-01
Last updated by the study team
2025-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.